日本心力衰竭诊疗实践与结局的时间趋势比较:JROADHF与JROADHF-NEXT研究
结果显示2019-21年队列1年死亡率和心衰再入院率分别下降26.7%和52.1%。指南推荐药物使用增加及患者教育与生存获益相关。
要点
- 2019-21年队列较2013年队列1年死亡率下降26.7%,心衰再入院率下降52.1%。
- RAS抑制剂、β受体阻滞剂、MRA使用率及心脏康复、营养指导均显著增加。
- 药物使用和营养指导与死亡率降低相关,队列效应是心衰再入院下降的最强预测因素。
核心结论
- 2013年至2019-21年间日本心衰患者长期结局改善,1年死亡率和心衰再入院率显著下降。
- 指南推荐药物治疗与生存获益相关,心衰再入院率显著下降与出院后管理和医疗体系的广泛变化相关。
研究设计与样本
- 采用1:1倾向评分匹配比较两队列患者结局,匹配后各队列2972例患者。
主要发现
- 匹配后2013年与2019-21年队列相比:RAS抑制剂使用率70.9%对73.1%,β受体阻滞剂74.9%对80.8%,MRA 54.2%对61.1%。
- 心脏康复参与率从43.5%增至88.8%,营养指导从2.9%增至56.1%。
- 2019-21年队列1年死亡率较2013年队列下降26.7%(P<.001),心衰再入院率下降52.1%(P<.001)。
关键数值与推荐
- 指南推荐治疗使用率(2013年对2019-21年):RAS抑制剂70.9%对73.1%,β受体阻滞剂74.9%对80.8%,MRA 54.2%对61.1%。
- 心脏康复率43.5%对88.8%,营养指导率2.9%对56.1%。
- 1年死亡率下降26.7%(P<.001),心衰再入院率下降52.1%(P<.001)。
临床怎么用
- 应持续提高心衰患者指南推荐药物使用率,包括RAS抑制剂、β受体阻滞剂和MRA。
- 重视心脏康复和营养指导等患者教育措施,其与死亡率降低相关。
- 心衰再入院率下降更多与出院后管理和医疗体系整体改进相关,提示需关注系统性管理优化。
局限性
- 本研究为注册研究的时间趋势比较,存在队列间未测量混杂因素的可能。
- 日本人群研究结果外推至其他人群需谨慎,原文未说明具体局限性条目。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Advances in therapeutics and interventions have enabled the comprehensive management of patients with heart failure (HF); however, real-world clinical practice remains poorly characterized. This study aimed to evaluate temporal changes in HF management and their impact on patient outcomes. METHODS: Two large-scale Japanese HF registries were compared: the JROADHF (2013, n = 13 238) and JROADHF-NEXT (2019-21, n = 4016). Propensity score matching (1:1) was performed to compare patient outcomes between cohorts and identify factors associated with outcome improvements. RESULTS: Propensity score matching yielded 2972 patients in each cohort. After matching, guideline-recommended therapy increased for renin-angiotensin system inhibitors (70.9% vs 73.1%), beta-blockers (74.9% vs 80.8%), mineralocorticoid receptor antagonists (54.2% vs 61.1%), cardiac rehabilitation (43.5% vs 88.8%), and nutritional guidance (2.9% vs 56.1%) in the 2013 and 2019-21 cohorts, respectively. The 2019-21 cohort demonstrated 26.7% and 52.1% reductions in 1-year mortality and HF readmission rate (P < .001 for both), respectively, compared with the 2013 cohort. Improved mortality was associated with pharmacotherapy [renin-angiotensin system inhibitors: hazard ratio (HR) .71, 95% confidence interval (CI) .64-.80, P < .001; beta-blockers: HR .85, 95% CI .75-.96, P = .012] and patient education (nutritional guidance: HR .76, 95% CI .64-.89, P = .001). The cohort effect was the strongest predictor of HF readmission (subdistribution HR .49, 95% CI: .43-.57, P < .001). CONCLUSIONS: Long-term outcomes of patients with HF improved between 2013 and 2019-21. Guideline-recommended therapy was associated with survival benefit, whereas marked reduction in HF readmission rates coincided with broader changes in post-discharge care and healthcare system.
引用
- Tohyama, Ikeda, Watanabe, et al. Temporal comparison of clinical practice and outcomes in heart failure: the JROADHF and JROADHF-NEXT studies. Eur Heart J. 2026. PMID: 42568038. doi:10.1093/eurheartj/ehag577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。